💸 The Tape

When the Georgia House of Representatives adopted House Resolution 24 on Friday — formally commending Medical Marijuana Therapeutics, a family-owned cannabis practice that has been serving patients since 2019 — it wasn't just a feel-good legislative moment. It was a signal of how deeply medical cannabis is embedding itself into Georgia's healthcare and political culture, even as the program remains one of the youngest and most restrictive in the country.

The resolution recognized Dr. Madelaine Murad, the practice's chief medical officer, for developing individualized cannabis treatment plans; Vicki Jacobson, chief operating officer, for leading outreach particularly among senior populations; and Melanie Jacobson, cannabis consultant, for patient advocacy and education. The practice's use of statewide telemedicine was specifically highlighted — a model that's critical in a state where dispensary density remains limited and rural patients face significant access barriers.

For a state legislature to formally honor a cannabis practice for contributions to patient safety, education, and responsible guidance tells you something about where Georgia's political center of gravity is heading. And for the companies already operating on the ground, the trajectory just got meaningfully steeper.

Trulieve's Georgia Positioning

No operator is better positioned to capitalize on Georgia's evolution than Trulieve (NYSE: TRLV).

The company holds a Class 1 production license — the larger of the state's two license tiers, authorizing up to 100,000 square feet of indoor cultivation — and operates an indoor cultivation and processing facility in Adel, Georgia as part of its vertically integrated model. Trulieve currently runs six dispensary locations across the state in Pooler, Newnan, Evans, Columbus, Marietta, and Macon, making it the largest dispensary operator in Georgia by location count.

When CEO Kim Rivers announced Trulieve's historic NYSE uplisting earlier this month, she specifically named Georgia and Texas alongside the company's existing strongholds as growth drivers — a deliberate signal that these emerging medical markets are central to the post-rescheduling strategy.

The timing aligns perfectly with SB 220, the "Putting Georgia's Patients First Act" signed by Governor Kemp, which takes effect July 1. The law removes end-stage and severity requirements from qualifying conditions, adds 15 new diagnoses including Parkinson's, ALS, HIV/AIDS, and fibromyalgia, and expands product formats including vaporization. Governor Beshear's executive order estimates the expansion could make over 400,000 additional Georgians eligible for the program — a potential tenfold increase from the current base of approximately 33,700 patients.

For Trulieve — with six dispensaries, a Class 1 cultivation license, and the infrastructure already built — that patient expansion translates directly into revenue growth without requiring significant additional capital investment. The company is already preparing new product launches timed to the July 1 effective date.

Florida: The Cash Flow Engine

If Georgia is the growth story, Florida is the foundation.

Trulieve operates approximately 240 dispensaries nationwide, and the overwhelming majority are in Florida — its home state and the market that generates the bulk of its $287 million in quarterly revenue and $100 million in quarterly adjusted EBITDA. Florida's medical cannabis program serves over 800,000 registered patients and generated approximately $2.25 billion in annual sales in 2025, making it the second-largest state cannabis market in the country behind only California.

Florida's limited-license structure has been a powerful competitive moat for operators like Trulieve that built scale early. The vertical integration requirement — cultivation, processing, and dispensing under one license — creates barriers to entry that protect established operators from the kind of margin-compressing competition seen in open-license states.

The state's 2024 recreational amendment received 56% voter support but fell short of the required 60% supermajority — leaving Florida medical-only for now. But with Schedule III rescheduling now eliminating 280E tax treatment on medical operations, Trulieve's Florida cash flow machine becomes even more profitable on an after-tax basis. And with over 3.5 million square feet of production capacity registered with the DEA, Trulieve has more medical cannabis infrastructure in Florida alone than most operators have nationwide.

Texas: The Long Game

Texas represents the most asymmetric opportunity in Trulieve's portfolio — and the most uncertain.

The state's Compassionate Use Program (TCUP) remains one of the most restrictive medical cannabis frameworks in America, with a patient population that represents less than 0.5% of the state's nearly 30 million residents. But the passage of House Bill 46 expanded qualifying conditions and imposed restrictions on competing hemp-derived THC products, while the recent TCUP license expansion added new operators to the market.

Trulieve was among the companies conditionally awarded new TCUP licenses following the Texas Department of Public Safety's corrected scoring tabulation in May — positioning it for vertically integrated operations in the nation's second-most-populous state. The conditional license authorizes cultivation, processing, and dispensing, and represents entry into a market where patient growth could accelerate dramatically if qualifying conditions continue to expand or if federal rescheduling eventually prompts broader Texas reform.

The Texas medical market generated relatively modest revenue in 2025, but the addressable population is enormous. With nearly 30 million residents and a political environment that — despite its conservative reputation — has been gradually expanding cannabis access through successive legislative sessions, Texas represents a market where early operators could build the kind of durable positioning that Trulieve achieved in Florida a decade ago.

The Southeast Growth Thesis

Zoom out and the strategic picture becomes clear. Trulieve has built — or is building — vertically integrated medical cannabis operations in three of the largest Southern states by population: Florida (22.6 million), Georgia (11.1 million), and Texas (30.5 million). Combined, these three states represent over 64 million Americans — roughly 20% of the U.S. population — in markets where limited licensing, vertical integration requirements, and early-mover advantages create structural moats that are exceptionally difficult to replicate.

Florida is generating cash now. Georgia is about to accelerate. Texas is the long-dated option with massive upside. And all three benefit from 280E elimination under Schedule III, with Trulieve already trading on the NYSE and filing DEA registrations across its medical footprint.

When Rivers said Trulieve is "well positioned to deliver on our promise to increase access to medical cannabis for U.S. patients," she wasn't speaking in generalities. She was describing a company with 240 dispensaries, 3.5 million square feet of production capacity, and strategic positions in three of the largest growth markets in American cannabis.

The Georgia House resolution commending a family medical cannabis practice is a small story. The market it represents — and the company best positioned to capture it — is anything but.

📈 Dog Walkers

$VREOD Closes In Maryland

Vireo Growth just added another line item to what may be the longest active acquisition ledger in cannabis.

The company announced the closing of its acquisition of an indirect 49% equity interest in HA-MD, LLC, the parent entity of Chesapeake Integrated Health Institute and Maryland Alternative Relief — two Maryland-based cannabis operations. The deal, originally announced in November 2025, closed for total consideration of $1.55 million — a rounding error on Vireo's balance sheet but another strategic foothold in a state where adult-use cannabis continues to ramp.

The purchase price was split across three components: $400,000 in cash at closing, $400,000 via a five-year promissory note at 8% interest, and the remaining $750,000 satisfied through the issuance of 37,035 Vireo subordinate voting shares at a deemed price of $20.25 per share on a post-consolidation basis.

At $1.55 million for a 49% stake, this isn't a headline-grabbing acquisition. But for Vireo — which has now closed or announced deals involving Schwazze, Eaze, Hawthorne, FLUENT, C21 Investments, Bridgewell Agribusiness, and the Glass House joint venture — it's another incremental piece in a national footprint that keeps expanding, one deal at a time.

Maryland makes the map a little bigger. The pace doesn't slow.

🗞️ The News

📺 Trade To Black

Why Consolidation Is Coming | TTB Weekly Recap

• Institutional Patience: Curaleaf CEO Boris Jordan says the real challenge isn't uplisting anymore — it's attracting firms like BlackRock and Fidelity, who are watching but waiting for additional clarity on rescheduling, banking, compliance, and federal policy before making meaningful equity commitments.

• Consolidation Inevitable: Industry voices including Seth Yakatan and Hirsh Jain agree the sector has too many operators, with mergers and acquisitions expected to accelerate as Schedule III economics and capital markets access favor scaled, well-capitalized companies.

• State-Level Growth Returning: Markets like Virginia, Minnesota, Ohio, and New York continue expanding, while upcoming hemp regulations could redirect billions in consumer spending back into regulated cannabis channels — creating tailwinds for licensed operators.

• Reform Momentum Building: Expanding DEA registrations, progress toward broader Schedule III through the June 29 ALJ hearing, Glass House's NYSE application, and growing lawmaker engagement all point to an industry entering its most consequential stretch of federal normalization yet.